OPO. R. Piruzieva

O. R. Piruzieva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


O. R. Piruzieva has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Kidney damage in tuberous sclerosis

    by S. L. Morozov, O. R. Piruzieva, L. S. Prikhodina

    Tuberous sclerosis is a rare genetic disease characterized by the development of benign tumors in various organs, including the kidneys. Renal lesions in tuberous sclerosis are most often represented by angiomyolipomas and cysts, which can lead to various complications, such as bleeding, renal failure and malignant transformation. This review article examines current concepts of the pathogenesis, clinical manifestations, diagnostics and treatment methods of renal lesions in tuberous sclerosis, as well as prospects for further research in this area.

  • Предикторы прогрессирования хронической болезни почек у детей с CAKUT. Курсова Т.С., Морозов С.Л., Пирузиева О.Р. и соавт.

    by Т.с. Курсова, С.л. Морозов, О.р. Пирузиева, С.в. Байко

    Врожденные аномалии почек и мочевых путей являются одной из наиболее частых причин развития хронической болезни почек, и пациенты с этими аномалиями лидируют в этиологической структуре терминальной почечной недостаточности. Этиология CAKUT до конца не изучена, но известно, что такие внешние факторы, как стресс, недостаточное питание, инфекции, воздействие химических веществ, лекарств или нарушения обмена веществ, могут оказывать влияние на процесс дифференцировки клеток плода и нарушать формирование мочевой системы. В настоящее время остается недостаточно изученным вопрос в отношении биологических «предикторов» прогрессирования хронической болезни почек у детей с CAKUT. Мы хотим представить анализ последних исследований, в которых изучались вопросы влияния различных факторов в пренатальный и постнатальный периоды развития и их влияние на прогрессирование хронической болезни почек.

  • Spectrum of clinical manifestations of X-linked Alport syndrome in girls: a single-center cohort study

    by M.E. Aksyonova, N.E. Konkova, O.R. Piruzeyeva, T.V. Lepayeva, T.A. Nikishina, V.A. Obukhova, L.S. Prikhodina

    X-linked Alport syndrome (XLAS) is an inherited disorder caused by genetic variants in gene COL4A5. The frequency and the severity of clinical manifestations as well as the risk of glomerulopathy progression are variable in XLAS in females, and the disease course features have not been sufficiently studied as yet. Since patient management tactics is determined by the disease course nature, studying the spectrum of XLAS clinical manifestations and prognosis in girls remains relevant. The purpose of this research was to determine the spectrum and the features of clinical manifestations of XLAS in girls. Materials and methods used: a single-center cohort prospective study was carried out by the Authors that included 74 girls aged 2 to 17 y/o with genetically proven XLAS diagnosis. Authors have analyzed the patients’ medical records identifying sensorineural hearing loss (SNHL), arterial hypertension (AH; blood pressure (BP) over 95% than at the patient’s age/height), albuminuria (Alb; norm<30 mg/mmol of creatinine), proteinuria (Pr; norm<100 mg/sq m/day) - with its degree, decrease in estimated glomerular filtration rate (eGFR, ml/min/1.73 sq m; norm≥90 ml/min/1.73 sq m) and angiotensin-converting enzyme inhibitors (ACEIs) therapy data. Results: all patients had hematuria with episodical macrohematuria in 27% of cases, proteinuria in 40%, eGFR decrease in 15%, SNHL in 8% and peripheral retinopathy in 7%. Girls with missense v. those with non-missense variants of COL4A5 more often had macrohematuria (0.15 v. 0.05; p=0.015) and albuminuria (1 v. 0.5; p<0.001) whilst no statistically significant difference was showed in proteinuria frequency and age of onset (0.48 v. 0.5 and 6.5 [3; 11] v. 5 [5; 8] y/o), eGFR decrease (0.15 v. 0.15; 12.4±2.6 v. 13.2 ±2.8 y/o), SNHL (0.07 v. 0.1; 13±2.8 v. 14.4±3.1 y/o) and retinopathy (0.04 v. 0.15; 14.3±3.5 v. 12.6±2.9 y/o). ACEIs therapy did not show any statistically significant effect on the cumulative proportion of patients with both proteinuria and eGFR decrease (log-rank test=1.25, p=0.213 and log-rank test=0.66, p=0.512, respectively). Conclusion: the results obtained demonstrate the need for a dynamic follow-up of girls with XLAS with the purpose of earliest possible detection of proteinuria and timely prescribing with nephroprotective therapy as well as hearing loss diagnosing and timely audiological correction.

  • Genetic variants of X-linked Alport syndrome in children: a single-center cohort study

    by M.E. Aksyonova, N.E. Konkova, O.R. Piruzeyeva, N.M. Zaykova, T.V. Lepayeva, T.A. Nikishina, V.A. Obukhova, L.S. Prikhodina

    X-linked Alport syndrome (XLAS) is a monogenic disease characterized by the progressive nephropathy development, sensorineural hearing loss and the lens and retina pathology. The clinical manifestations of the syndrome and the renal prognosis of patients are determined by the nature of the gene COL4A5 mutation. The range of COL4A5 genetic variants is different among populations. Information about the XLAS genetic structure in Russian pediatric cohort is insufficient. The purpose of this research was to determine the features of the spectrum of the gene COL4A5 genetic variants in children with XLAS. Materials and methods used: a single-center retrospective cohort study included children aged 2 to 17 y/o with genetically confirmed XLAS. Descriptions of variants in gene COL4A5 were performed using genome build GRCh37/hg19 in accordance with the reference sequence GRCh37/hg19 (Reference Sequence, HGVS) and the American College of Medical Genetics and Genomics (ACMG), AMP Clinical Practice Guidelines. Results: analysis of data from 174 probands from unrelated families showed that 108 (62%) children had missense variants in gene COL4A5 (62% v. 38%, missense v. non-missense variants, respectively, p=0.028), 24 (13.8%) had mutations leading to impaired RNA splicing, 17 (9.8%) had frameshift mutations, 14 (8%) had gene deletions and 10 (5.7%) had nonsense mutations. Missense variants were predominantly localized in the collagen domain compared to the non-collagen domain (n=102, 94.4%, pA (p.Gly624Asp) in 28 (26%) and NM_033380.3(COL4A5):c.3319G>A (p.Gly1107Arg) in 4 (3.7%). Conclusion: the structure of COL4A5 genetic variants in the studied cohort was comparable with the current Worldwide data, such as two thirds of the examined had missense variants and ca. one-fifth had genetic variants leading to the protein synthesis absence. Two common missense variants in gene COL4A5 were identified, including the common variant NM_033380.3(COL4A5):c.1871G>A (p.Gly624Asp) that is of frequent occurrence in the European population.

  • RISK FACTORS FOR POOR NEPHROLOGICAL PROGNOSIS IN BOYS WITH X-LINKED ALPORT SYNDROME: A SINGLE CENTER COHORT STUDY

    by M.E. Aksenova, N.E. Konkova, O.R. Piruzeeva, N.M. Zaikova, T.V. Lepaeva, T.A. Nikishina, V.A. Obukhova, V.V. Dlin

  • ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN PREVENTING PROTEINURIA IN BOYS WITH X-LINKED ALPORT SYNDROME: A SINGLE-CENTER COHORT NON-RANDOMIZED STUDY

    by M.E. Aksenova, N.E. Konkova, O.R. Piruzeeva, N.M. Zaikova, T.V. Lepaeva, T.A. Nikishina, V.A. Obukhova, V.V. Dlin

    Patients with a hemizygous mutation in the COL4A5 gene have a high risk of developing renal failure at a young age. Proteinuria reflects the progression of glomerulopathy in Alport syndrome (AS). In order to improve renal survival in AS patients with proteinuria are prescribed with angiotensin system inhibitors. There is a limited, insufficient number of studies demonstrating the effectiveness of angiotensin-converting enzyme inhibitors (ACEI) in children with AS; the therapeutic effect initiated prior to the development of proteinuria has not been studied as yet. The purpose of the research was to determine the effectiveness of ACEI therapy in the form of enalapril in the prevention of proteinuria in boys with X-linked AS (XLAS). Materials and methods used: boys aged 2 to 15 y/o with genetically confirmed XLAS were included in a single-center prospective cohort study. Enalapril was prescribed at doses of 1 to 3 mg/m2/day. Urinary protein excretion (Pr) and estimated glomerular filtration rate (eGFR) were studied at the time of inclusion and with a frequency of one time per six months for the three-year period or longer. The primary endpoint was the time of onset of proteinuria. Results: 72 boys in total, incl. 29 without proteinuria, who received enalapril therapy (Group 1, age 6.2±1.9 y/o, Pr 67±20 mg/m2/day, eGFR 118±15.2 ml /min/1.73 m2) and 43 children without therapy (Group 2, age 6.8±1.9 y/o, Pr 87±23 mg/m2/day, eGFR 119±17.3 ml/min/1.73 m2). The incidence of proteinuria (0.45 in G1 vs. 0.98 in G2, p<0.001), incl. up to the age of 10 y/o (0.42 vs 0.91, respectively, p<0.001) was statistically significantly lower in G1. Proteinuria developed later in the treatment group (10.2±2.9 vs. 4.9±1.4 years, p=0.300). Non-missense mutations in the COL4A5 gene, episodes of macrohematuria in records and lack of therapy were the risk factors for proteinuria; the lack of enalapril therapy was a predictor for proteinuria. The risk of proteinuria during therapy was reduced by 50% (RR=0.46 (95% CI 0.31; 0.68); ARR=0.53; NNT=1.9). Conclusion: initiation of enalapril therapy at the pre-proteinuria stage of nephropathy in boys with XLAS reduces the risk of proteinuria preventing its occurrence in every 50$ of cases when receiving treatment. Early initiation of therapy may be effective in preventing the progression of kidney disease in boys with XLAS.

  • Epigenetic markers of podocyte repair in children with primary nephrotic syndrome

    by S. L. Morozov, V. V. Dlin, V. Yu. Voinova, A. V. Smirnova, O. R. Piruzieva

    In terms of a glomerular injury research model, idiopathic nephrotic syndrome is the most prominent example. Worldwide, nephrotic syndrome is a socially significant disease and is considered one of the most common glomerulopathies in childhood, leading to the development of chronic kidney disease, and in the case of progression of the disease, to the formation of terminal chronic renal failure. This article presents data from our own study and discusses epigenetic markers of podocyte repair in children with primary nephrotic syndrome. We noted that in patients with steroid-sensitive variants of nephrotic syndrome, the expression of the WT1 (podocyte transcription factor) and NPHS1 (the gene encoding nephrin — a transmembrane protein that is a structural component of the slit diaphragm of the podocyte) genes is significantly higher than in the control group and in children with steroid resistant nephrotic syndrome. The data obtained open up prospects for the development of a personalized approach to the management of children with primary nephrotic syndrome by determining the markers of the staging and/or severity of the pathological process occurring in the glomeruli. Currently, genomic and post-genomic technologies are increasingly being used in clinical practice, which will eventually lead to the development of personalized diagnostic panels based on innovative technologies.

  • Mycophenolate mofetil in therapy of primary nephrotic syndrome in children

    by S. L. Morozov, T. S. Kursova, E. K. Petrosyan, O. R. Piruzieva, V. V. Dlin

    Idiopathic nephrotic syndrome is the most common glomerular disease in children, with a prevalence of 1.15–16.9 cases per 100,000 children per year worldwide. In some cases, nephrotic syndrome has a frequently relapsing course or dependence on steroid therapy is formed, which leads to the appointment of immunosuppressive therapy. So far, in clinical practice, there is no unambiguous approach among physicians to the management of patients with nephrotic syndrome, especially when it comes to the further choice of immunosuppressive therapy. Because of the serious side effects of long-term corticosteroid use, doctors prescribe steroid adjuvants to maintain remission and limit the cumulative effect of glucocorticosteroids. Among adjuvants, mycophenolate mofetil, with mycophenolic acid as the active ingredient, is believed to be the most preferred option due to fewer adverse events, acceptable tolerability and, at the same time, high efficacy. This article describes the advantages and features of the use of mycophenolic acid in clinical practice, provides data on pharmacodynamics and drug monitoring, and discusses issues of personalized medicine.


  • Проблемы поликистоза почек у детей с туберозным склерозом на современном этапе

    by С.л. Морозов, О.р. Пирузиева, М.ю. Дорофеева, О.в. Катышева, О.в. Тарасова, Е.с. Сахарова, В.в. Длин

    Туберозный склероз (ТС) является редким мультисистемным заболеванием с аутосомно-доминантным типом наследования, характеризующимся образованием гамартом во многих органах и тканях, включая кожу, головной мозг, почки, легкие и сердце. Имеет разнообразные клинические проявления. Особое место в поражении почек при туберозном склерозе является появление множественных кист — как изолированных, так и в сочетании с ангиомиолипомами, которые вносят существенный вклад в тяжесть течения болезни. Важным моментом развития туберозного склероза с поражением почек считается формирование вторичных осложнений, возникающих на фоне основного заболевания. В представленном обзоре показана актуальность проблемы поликистоза почек при ТС, рассмотрен его патогенез, представлены основные принципы и перспективы лечения.

  • Ammonium glycyrrhizinate in the complex treatment of steroid-dependent nephrotic syndrome in children

    by S.L. Morozov, O.R. Piruzieva, T.V. Lepaeva, T.A. Nikishina

    The development of resistance to steroid therapy and the formation of dependence (“withdrawal syndrome”) due to secondary adrenal insufficiency on the background of long-term treatment with prednisolone is a topical issue in the management of patients with nephrotic syndrome (NS). Patients and methods. This observational study included 40 children aged 5 to 10 years diagnosed with steroid-dependent nephrotic syndrome (SDNS). The patients were divided into two groups: the study group (n = 20) and the control group (n = 20). All patients received prednisolone in alternating regimens followed by its withdrawal and mofetilic acid medication; patients in the study group additionally received ammonium glycyrrhizinate (AG) over a 24-week course. The follow-up period was 24 weeks with 5 on-site visits (day 0; weeks 2, 4, 12, and 24), during which the cases of disease exacerbations, their duration, the level of proteinuria, and the development of side effects were recorded. The expression levels of ABCB1, NR3C1, CYP3A4, NR1I2 genes were assessed at the 1st and 5th visits in the study group. Results. In the first 1.5 months after prednisolone withdrawal, no child in the study group experienced a recurrence of NS against the background of ammonium glycyrrhizinate therapy, while the control group had a 25% frequency of NS recurrence (n = 5 ) ( p = 0.043). In the study group, the median length of NS remission after prednisolone withdrawal was more than 2.5 months (85.2 ± 39.9 days), while in the control group, NS recurrence occurred more than 2.5 times faster, and remission was only 33 ± 12.3 days (p = 0.009). No statistically significant differences in gene expression (ABCB1, NR3C1, CYP3A4, NR1I2) were found before and after AG treatment in patients in the study group. Conclusion. The inclusion of ammonium glycyrrhizinate during the period of prednisolone therapy withdrawal in patients with SDNS helps to reduce the recurrence rate (glucocorticosteroid withdrawal syndrome) of the disease and significantly prolongs the length of remission. The long-term use of the medication does not lead to an increase in the expression of genes associated with the development of hormone resistance. Key words: children, steroid-dependent nephrotic syndrome, prevention, prednisolone, ammonium glycyrrhizinate